Global Therapeutic Drug Monitoring Market Size Study, by Product (Equipment, Consumables), by Drug Class (Antiarrhythmic Drugs, Immunosuppressants, Antiepileptic Drugs, Others), by End Use (Hospitals, Diagnostic Centers, Others), and Regional Forecasts 2022-2032
The global therapeutic drug monitoring (TDM) market, valued at USD 1.80 billion in 2023, is projected to grow to USD 2.52 billion by 2032, at a compound annual growth rate (CAGR) of 3.8% during the forecast period 2024–2030. Therapeutic drug monitoring is a critical component of personalized medicine, ensuring the optimization of drug dosage and safety for various medical conditions. TDM involves measuring specific drug levels in a patient's blood to maintain therapeutic concentrations while minimizing toxicity.
Key growth drivers include the rising prevalence of chronic diseases such as diabetes, cancer, and cardiovascular disorders, coupled with technological advancements in diagnostic tools. The increasing adoption of genetic testing and personalized medicine also contributes significantly to market expansion. For example, innovative methods like AMPLON DNA amplification have improved the accuracy and efficiency of diagnostic testing. Furthermore, supportive regulatory policies and investments in healthcare infrastructure fuel the demand for TDM services globally.
North America dominated the global TDM market in 2023, accounting for 42.7% of the revenue share, owing to heightened awareness, government regulations, and technological advancements in diagnostic equipment. The Asia-Pacific region is expected to witness the highest growth during the forecast period, driven by an aging population, increasing cases of chronic illnesses, and improvements in healthcare infrastructure.
Major market players included in this report are:
By Product:
Key growth drivers include the rising prevalence of chronic diseases such as diabetes, cancer, and cardiovascular disorders, coupled with technological advancements in diagnostic tools. The increasing adoption of genetic testing and personalized medicine also contributes significantly to market expansion. For example, innovative methods like AMPLON DNA amplification have improved the accuracy and efficiency of diagnostic testing. Furthermore, supportive regulatory policies and investments in healthcare infrastructure fuel the demand for TDM services globally.
North America dominated the global TDM market in 2023, accounting for 42.7% of the revenue share, owing to heightened awareness, government regulations, and technological advancements in diagnostic equipment. The Asia-Pacific region is expected to witness the highest growth during the forecast period, driven by an aging population, increasing cases of chronic illnesses, and improvements in healthcare infrastructure.
Major market players included in this report are:
- Abbott
- ALPCO
- Beckman Coulter, Inc.
- Bio-Rad Laboratories, Inc.
- Thermo Fisher Scientific Inc.
- Chromsystems Instruments & Chemicals GmbH
- F. Hoffmann-La Roche Ltd.
- Randox Laboratories Ltd.
- Siemens Healthineers AG
- biomйrieux, Inc.
By Product:
- Equipment
- Immunoassay Analyzers
- Clinical Chemistry Analyzers
- Chromatography & MS Detectors
- Consumables
- Antiarrhythmic Drugs
- Immunosuppressants
- Antiepileptic Drugs
- Others
- Hospitals
- Diagnostic Centers
- Others
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
- Historical year – 2022
- Base year – 2023
- Forecast period – 2024 to 2032
- Detailed analysis of market segments with revenue forecasts from 2024 to 2030.
- Country-level insights and competitive analysis.
- Trends in diagnostic equipment and consumables driving growth in TDM.
CHAPTER 1. GLOBAL THERAPEUTIC DRUG MONITORING MARKET EXECUTIVE SUMMARY
1.1. Global Therapeutic Drug Monitoring Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Product
1.3.2. By Drug Class
1.3.3. By End Use
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendations & Conclusion
CHAPTER 2. GLOBAL THERAPEUTIC DRUG MONITORING MARKET DEFINITION AND RESEARCH ASSUMPTIONS
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply-Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer’s Perspective)
2.3.4. Demand-Side Analysis
2.3.4.1. Regulatory Frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
CHAPTER 3. GLOBAL THERAPEUTIC DRUG MONITORING MARKET DYNAMICS
3.1. Market Drivers
3.1.1. Increasing Prevalence of Chronic Diseases
3.1.2. Growth in Personalized Medicine and Genetic Testing
3.1.3. Technological Advancements in Diagnostic Equipment
3.2. Market Challenges
3.2.1. High Cost of Advanced Equipment
3.2.2. Limited Access to Healthcare in Developing Economies
3.3. Market Opportunities
3.3.1. Expansion in Emerging Markets
3.3.2. Adoption of Advanced Drug Monitoring Techniques
CHAPTER 4. GLOBAL THERAPEUTIC DRUG MONITORING MARKET INDUSTRY ANALYSIS
4.1. Porter’s Five Forces Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s Five Forces Model
4.1.7. Porter’s Five Forces Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economic
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Winning Strategies
4.5. Analyst Recommendations & Conclusion
CHAPTER 5. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE & FORECAST BY PRODUCT (2022-2032)
5.1. Segment Dashboard
5.2. Global Therapeutic Drug Monitoring Market: Product Revenue Analysis (2022-2032)
5.2.1. Equipment
5.2.1.1. Immunoassay Analyzers
5.2.1.2. Clinical Chemistry Analyzers
5.2.1.3. Chromatography & MS Detectors
5.2.2. Consumables
CHAPTER 6. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE & FORECAST BY DRUG CLASS (2022-2032)
6.1. Segment Dashboard
6.2. Global Therapeutic Drug Monitoring Market: Drug Class Revenue Analysis (2022-2032)
6.2.1. Antiarrhythmic Drugs
6.2.2. Immunosuppressants
6.2.3. Antiepileptic Drugs
6.2.4. Others
CHAPTER 7. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE & FORECAST BY END USE (2022-2032)
7.1. Segment Dashboard
7.2. Global Therapeutic Drug Monitoring Market: End Use Revenue Analysis (2022-2032)
7.2.1. Hospitals
7.2.2. Diagnostic Centers
7.2.3. Others
CHAPTER 8. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE & FORECAST BY REGION (2022-2032)
8.1. North America
8.1.1. U.S.
8.1.2. Canada
8.1.3. Mexico
8.2. Europe
8.2.1. UK
8.2.2. Germany
8.2.3. France
8.2.4. Italy
8.2.5. Spain
8.2.6. Denmark
8.2.7. Sweden
8.2.8. Norway
8.3. Asia Pacific
8.3.1. Japan
8.3.2. China
8.3.3. India
8.3.4. Australia
8.3.5. South Korea
8.3.6. Thailand
8.4. Latin America
8.4.1. Brazil
8.4.2. Argentina
8.5. Middle East & Africa
8.5.1. South Africa
8.5.2. Saudi Arabia
8.5.3. UAE
8.5.4. Kuwait
CHAPTER 9. COMPETITIVE INTELLIGENCE
9.1. Key Company SWOT Analysis
9.1.1. Abbott
9.1.2. Thermo Fisher Scientific Inc.
9.1.3. Bio-Rad Laboratories, Inc.
9.2. Top Market Strategies
9.3. Company Profiles
9.3.1. ALPCO
9.3.2. Beckman Coulter, Inc.
9.3.3. F. Hoffmann-La Roche Ltd.
9.3.4. Siemens Healthineers AG
9.3.5. biomйrieux, Inc.
CHAPTER 10. RESEARCH PROCESS
10.1. Research Overview
10.2. Data Collection Techniques
10.3. Market Estimation Techniques
10.4. Validation Methodology
1.1. Global Therapeutic Drug Monitoring Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Product
1.3.2. By Drug Class
1.3.3. By End Use
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendations & Conclusion
CHAPTER 2. GLOBAL THERAPEUTIC DRUG MONITORING MARKET DEFINITION AND RESEARCH ASSUMPTIONS
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply-Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer’s Perspective)
2.3.4. Demand-Side Analysis
2.3.4.1. Regulatory Frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
CHAPTER 3. GLOBAL THERAPEUTIC DRUG MONITORING MARKET DYNAMICS
3.1. Market Drivers
3.1.1. Increasing Prevalence of Chronic Diseases
3.1.2. Growth in Personalized Medicine and Genetic Testing
3.1.3. Technological Advancements in Diagnostic Equipment
3.2. Market Challenges
3.2.1. High Cost of Advanced Equipment
3.2.2. Limited Access to Healthcare in Developing Economies
3.3. Market Opportunities
3.3.1. Expansion in Emerging Markets
3.3.2. Adoption of Advanced Drug Monitoring Techniques
CHAPTER 4. GLOBAL THERAPEUTIC DRUG MONITORING MARKET INDUSTRY ANALYSIS
4.1. Porter’s Five Forces Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s Five Forces Model
4.1.7. Porter’s Five Forces Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economic
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Winning Strategies
4.5. Analyst Recommendations & Conclusion
CHAPTER 5. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE & FORECAST BY PRODUCT (2022-2032)
5.1. Segment Dashboard
5.2. Global Therapeutic Drug Monitoring Market: Product Revenue Analysis (2022-2032)
5.2.1. Equipment
5.2.1.1. Immunoassay Analyzers
5.2.1.2. Clinical Chemistry Analyzers
5.2.1.3. Chromatography & MS Detectors
5.2.2. Consumables
CHAPTER 6. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE & FORECAST BY DRUG CLASS (2022-2032)
6.1. Segment Dashboard
6.2. Global Therapeutic Drug Monitoring Market: Drug Class Revenue Analysis (2022-2032)
6.2.1. Antiarrhythmic Drugs
6.2.2. Immunosuppressants
6.2.3. Antiepileptic Drugs
6.2.4. Others
CHAPTER 7. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE & FORECAST BY END USE (2022-2032)
7.1. Segment Dashboard
7.2. Global Therapeutic Drug Monitoring Market: End Use Revenue Analysis (2022-2032)
7.2.1. Hospitals
7.2.2. Diagnostic Centers
7.2.3. Others
CHAPTER 8. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE & FORECAST BY REGION (2022-2032)
8.1. North America
8.1.1. U.S.
8.1.2. Canada
8.1.3. Mexico
8.2. Europe
8.2.1. UK
8.2.2. Germany
8.2.3. France
8.2.4. Italy
8.2.5. Spain
8.2.6. Denmark
8.2.7. Sweden
8.2.8. Norway
8.3. Asia Pacific
8.3.1. Japan
8.3.2. China
8.3.3. India
8.3.4. Australia
8.3.5. South Korea
8.3.6. Thailand
8.4. Latin America
8.4.1. Brazil
8.4.2. Argentina
8.5. Middle East & Africa
8.5.1. South Africa
8.5.2. Saudi Arabia
8.5.3. UAE
8.5.4. Kuwait
CHAPTER 9. COMPETITIVE INTELLIGENCE
9.1. Key Company SWOT Analysis
9.1.1. Abbott
9.1.2. Thermo Fisher Scientific Inc.
9.1.3. Bio-Rad Laboratories, Inc.
9.2. Top Market Strategies
9.3. Company Profiles
9.3.1. ALPCO
9.3.2. Beckman Coulter, Inc.
9.3.3. F. Hoffmann-La Roche Ltd.
9.3.4. Siemens Healthineers AG
9.3.5. biomйrieux, Inc.
CHAPTER 10. RESEARCH PROCESS
10.1. Research Overview
10.2. Data Collection Techniques
10.3. Market Estimation Techniques
10.4. Validation Methodology
